Predictive Maintenance: Key AI Part In Pharma Manufacturing

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

Billerud Introduces New Pharmaceutical Packaging Option

Billerud has officially introduced PharmaKraft, a specialized fibre-based packaging...

AstraZeneca Advances AI Drug Discovery Deal with insitro

AstraZeneca has inked a billion-dollar AI drug discovery partnership...

Managing Quality and Regulatory Risks in Pharmaceutical Technology Transfer

Technology transfer moves more than manufacturing instructions. It moves process knowledge, supplier dependencies, labeling requirements, packaging specifications, and the evidence needed to demonstrate control. For medical device manufacturers, including those supporting drug-device combination products, these interfaces can become recurring sources of compliance gaps during site transitions, acquisitions, and remediation. The central problem is often not a missing procedure. It is a quality system that allows connected activities to change independently. A label revision may be approved while packaging artwork, supplier instructions, or production-system data still reflect an obsolete version. Staying inspection-ready requires manufacturers to manage these dependencies as one controlled system. Why Compliance Gaps Keep Recurring Findings are treated as documentation defects Revising a procedure can resolve an immediate discrepancy without changing the behavior that caused it. If unclear decision rights, weak escalation, or ineffective training remain, the same failure may surface elsewhere. Corrective and preventive action should distinguish the observed finding from its underlying cause and establish how effectiveness will be demonstrated. Ownership is divided across connected functions Quality, Regulatory Affairs, labeling, packaging engineering, operations, suppliers, and digital-system owners often maintain separate workflows. Each team may complete its assigned task while an interface remains uncontrolled. For example, changing an instruction for use can affect packaging configuration, translations, technical documentation, inventory disposition, and release controls. Transitions expose unresolved weaknesses Acquisitions and site transfers can introduce conflicting procedures, incomplete knowledge transfer, or different assumptions about validated processes. Regulatory changes add further demands. When these events coincide with CAPA or change-control backlogs, teams may prioritize administrative closure over risk reduction. Without a coordinated impact assessment, local fixes can create new gaps downstream. Establish the Regulatory Baseline Inspection readiness starts with knowing which requirements apply to the product, activity, and market. Pharmaceutical, device, and combination-product obligations are not interchangeable; transfer planning should identify the applicable requirements rather than assume one quality framework covers every operation. According to FDA’s Quality Management System Regulation overview and FAQs, the QMSR became effective on February 2, 2026, incorporates ISO 13485:2016 by reference, and introduced the updated device inspection process under Compliance Program 7382.850. ISO 13485 certification does not exempt a manufacturer from FDA inspection or guarantee compliance with FDA requirements. For devices marketed in the European Union, Regulation (EU) 2017/745, Annex I, Section 23, provides the primary requirements for information supplied with devices, including labels and instructions for use. Teams should assess the applicable provisions alongside relevant language, product-specific, and market requirements. A labeling review should therefore evaluate required content and consistency with the device’s intended purpose and supporting documentation—not merely artwork accuracy. How to Identify the Real Gaps Begin with a cross-functional assessment that follows actual product and information flows. Select representative transfers, label changes, supplier changes, and CAPAs, then trace each from initiation through implementation and effectiveness review. Map dependencies: Identify affected specifications, suppliers, packaging components, systems, validation activities, and training. Compare records with practice: Check whether approved procedures match what operators and reviewers actually do. Test traceability: Follow a requirement through technical documentation, labeling, production instructions, and release evidence. Examine recurrence: Look for repeated deviations, reopened actions, overdue changes, and findings shared across sites. Assess capacity: Determine whether qualified owners have enough time and authority to complete corrective work. Prioritize gaps by potential patient or user harm, regulatory impact, likelihood of recurrence, and detectability. Document the rationale; an old overdue item is not automatically more important than a newly identified high-risk weakness. Align Quality, Labeling, Packaging, and Change Control Create a coordinated remediation plan with one accountable owner for each action, named contributors, acceptance criteria, and required evidence. Separate immediate containment from systemic correction. Containment might prevent obsolete labels from being issued; correction might redesign approval and implementation controls so obsolete versions cannot return. Use change control as the integration point. Before approval, evaluate effects on regulatory submissions or notifications, technical documentation, supplier controls, packaging performance, validation, electronic master data, inventory, and training. Record both identified impacts and justified decisions that particular activities are unaffected. During technology transfer, define readiness gates before production or release responsibilities move. These should address the transfer of process knowledge, acceptance criteria, receiving-site capability, required qualification or validation, approved documents, and personnel competence. The appropriate evidence depends on the product and process; a generic checklist cannot replace a documented assessment. Finally, verify implementation where the work happens. Confirm that current instructions are available, suppliers received approved requirements, systems contain correct versions, and affected personnel can perform their tasks. A signed approval is not evidence that every downstream change took effect. Mistakes That Undermine Inspection Readiness Closing CAPAs on task completion alone: Effectiveness checks should test whether the underlying failure has been controlled. Updating labels in isolation: Assess packaging, supplier, system, documentation, and inventory consequences. Counting closures instead of evidence: Dashboards need defensible records behind their status indicators. ...
- Advertisement -

Pharmaceutical manufacturing happens to be a highly challenging and precise process that is crucial and has a prominent impact across various industries. One of the significant achievements of the modern era happens to be the development and production of dependable medicine, and this accomplishment has immensely enhanced public health and quality of life by putting into use innovation, expertise, as well as technology.

It is well to be noted that pharmaceutical manufacturing must adhere to strict standards to ensure the quality as well as safety of the final product. However, this can make the process difficult and at times inefficient. AI is playing a crucial role in pharmaceutical manufacturing, just like in various other industries and making remarkable progress in enhancing efficiency, quality, and other aspects of the manufacturing process. As a result, it is enabling the production of more effective goods, which can go on to reach a larger number of people in a shorter period of time.

The pharmaceutical manufacturing process

To fully explore the role of AI in pharma manufacturing, it is crucial to first have an absolute understanding of the pharmaceutical manufacturing process. Pharmaceutical manufacturing is subject to loads of stringent regulations, certifications as well as guidelines. Every step of the manufacturing process, whether it has medicines or medical products, must be carefully controlled.

The typical cycle for pharma product development and production follows these steps:

  • Product determination
  • Product development
  • Clinical trials
  • Patenting
  • Product formulation
  • Manufacturing/production
  • Quality control
  • Packaging & Fulfilment

The production as well as packaging processes deserve careful attention as many of the steps involved are crucial and also subject to strict regulations, such as:

  • Powder feeding
  • Active Pharmaceutical Ingredient- API or Ingredients are combined with excipients.
  • Milling
  • Hot melt extrusion
  • The delivery method, such as capsule, tablet, or other formats, is formulated by compressing the powder into the required shape.
  • Ensuring packaging and labelling comply with regulations.

Potential impacts when it comes to AI on pharmaceutical and medical manufacturing

Artificial intelligence- AI has the potential to impactfully influence the pharmaceutical and medical manufacturing industries through various means.

Predictive maintenance: It goes on to make use of industrial sensors, condition monitoring, analytics, as well as communication to pinpoint potential maintenance problems at a nascent stage, even before they go on to affect production. This enables managers as well as technicians to take proactive measures so as to address these issues. Predictive maintenance offers several benefits such as enhanced productivity, minimised downtime, as well as reduced maintenance expenses. AI can be utilised to identify potential problem states, detect the occurrence of these states, provide assistance in troubleshooting and diagnosis, and also support maintenance training.

Asset management strategy: It is crucial for pharma manufacturers as it helps them prolong the useful life of their equipment and components. This, in turn, allows them to maximise their return on investment. AI is being utilised in asset management in multiple ways like identifying the most suitable time so as to perform maintenance and take equipment out of service, helping with inventory management, supply chain as well as sourcing, enabling technicians to troubleshooting potential problems, and detecting as well as preventing shutdowns or safety concerns well in advance.

Advanced analytics: It happens to be crucial in modern manufacturing facilities, including the pharma sector. AI is demonstrating its exceptional usefulness when it comes to advanced analytics from multiple inputs, resulting in more effective insights than ever before.

There are several real-world examples of AI being used in the medical and pharmaceutical manufacturing setups.

Monitoring complex precision systems: This is crucial in the pharmaceutical and medical manufacturing landscape These industries rely on a huge network of interconnected systems to function with utmost precision. The network includes various components such as compressors, boilers, pumps, water systems as well as point-of-production equipment. The utilisation of AI along with machine learning in predictive maintenance can effectively boost the lifespan of systems and equipment. Additionally, it can lead to significant benefits when it comes to key efficiency and productivity metrics, such as the mean time between failure- MTTF.

Maintenance troubleshooting as well as diagnostics: This involves identifying as well as resolving equipment performance failures or even problems. Once technicians detect these challenges, they initiate the process of troubleshooting and diagnosing problem in order to find a solution. Predictive maintenance poses an even greater issue due to the need for early detection. AI assistance can enhance the process of identifying potential root causes and enable technicians to proceed more quickly and efficiently.

Spurring Innovation: AI can go on to assist in spurring innovation by analysing data from clinical trials and various stages of pharmaceutical product development cycle. This analysis has the potential to take into account new and more effective drugs, as well as other medical products. AI has the capability to rapidly synthesise large amounts of diverse information, which presents new opportunities for manufacturers to further enhance public health.

The use of augmented reality and virtual reality in the field of medical manufacturing

Apart from AI, virtual reality along with augmented reality can offer numerous benefits in the field of pharma manufacturing. One of the most important aspects is training, which goes on to involve assisting new hires in acquiring the necessary knowledge and experience needed for their tasks in a timely manner.

AR is particularly pivotal in this field because it can replicate real-life production line conditions or other tasks, allowing employees to gain practical experience without causing any disruptions or delays when it comes to production. This practice allows employees to learn more quickly without compromising efficiency or even quality. The fact is that Augmented Reality and Virtual Reality play crucial roles in the digital transformation of pharmaceutical manufacturing.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Latest stories

Related stories

Billerud Introduces New Pharmaceutical Packaging Option

Billerud has officially introduced PharmaKraft, a specialized fibre-based packaging...

AstraZeneca Advances AI Drug Discovery Deal with insitro

AstraZeneca has inked a billion-dollar AI drug discovery partnership...

Managing Quality and Regulatory Risks in Pharmaceutical Technology Transfer

Technology transfer moves more than manufacturing instructions. It moves process knowledge, supplier dependencies, labeling requirements, packaging specifications, and the evidence needed to demonstrate control. For medical device manufacturers, including those supporting drug-device combination products, these interfaces can become recurring sources of compliance gaps during site transitions, acquisitions, and remediation. The central problem is often not a missing procedure. It is a quality system that allows connected activities to change independently. A label revision may be approved while packaging artwork, supplier instructions, or production-system data still reflect an obsolete version. Staying inspection-ready requires manufacturers to manage these dependencies as one controlled system. Why Compliance Gaps Keep Recurring Findings are treated as documentation defects Revising a procedure can resolve an immediate discrepancy without changing the behavior that caused it. If unclear decision rights, weak escalation, or ineffective training remain, the same failure may surface elsewhere. Corrective and preventive action should distinguish the observed finding from its underlying cause and establish how effectiveness will be demonstrated. Ownership is divided across connected functions Quality, Regulatory Affairs, labeling, packaging engineering, operations, suppliers, and digital-system owners often maintain separate workflows. Each team may complete its assigned task while an interface remains uncontrolled. For example, changing an instruction for use can affect packaging configuration, translations, technical documentation, inventory disposition, and release controls. Transitions expose unresolved weaknesses Acquisitions and site transfers can introduce conflicting procedures, incomplete knowledge transfer, or different assumptions about validated processes. Regulatory changes add further demands. When these events coincide with CAPA or change-control backlogs, teams may prioritize administrative closure over risk reduction. Without a coordinated impact assessment, local fixes can create new gaps downstream. Establish the Regulatory Baseline Inspection readiness starts with knowing which requirements apply to the product, activity, and market. Pharmaceutical, device, and combination-product obligations are not interchangeable; transfer planning should identify the applicable requirements rather than assume one quality framework covers every operation. According to FDA’s Quality Management System Regulation overview and FAQs, the QMSR became effective on February 2, 2026, incorporates ISO 13485:2016 by reference, and introduced the updated device inspection process under Compliance Program 7382.850. ISO 13485 certification does not exempt a manufacturer from FDA inspection or guarantee compliance with FDA requirements. For devices marketed in the European Union, Regulation (EU) 2017/745, Annex I, Section 23, provides the primary requirements for information supplied with devices, including labels and instructions for use. Teams should assess the applicable provisions alongside relevant language, product-specific, and market requirements. A labeling review should therefore evaluate required content and consistency with the device’s intended purpose and supporting documentation—not merely artwork accuracy. How to Identify the Real Gaps Begin with a cross-functional assessment that follows actual product and information flows. Select representative transfers, label changes, supplier changes, and CAPAs, then trace each from initiation through implementation and effectiveness review. Map dependencies: Identify affected specifications, suppliers, packaging components, systems, validation activities, and training. Compare records with practice: Check whether approved procedures match what operators and reviewers actually do. Test traceability: Follow a requirement through technical documentation, labeling, production instructions, and release evidence. Examine recurrence: Look for repeated deviations, reopened actions, overdue changes, and findings shared across sites. Assess capacity: Determine whether qualified owners have enough time and authority to complete corrective work. Prioritize gaps by potential patient or user harm, regulatory impact, likelihood of recurrence, and detectability. Document the rationale; an old overdue item is not automatically more important than a newly identified high-risk weakness. Align Quality, Labeling, Packaging, and Change Control Create a coordinated remediation plan with one accountable owner for each action, named contributors, acceptance criteria, and required evidence. Separate immediate containment from systemic correction. Containment might prevent obsolete labels from being issued; correction might redesign approval and implementation controls so obsolete versions cannot return. Use change control as the integration point. Before approval, evaluate effects on regulatory submissions or notifications, technical documentation, supplier controls, packaging performance, validation, electronic master data, inventory, and training. Record both identified impacts and justified decisions that particular activities are unaffected. During technology transfer, define readiness gates before production or release responsibilities move. These should address the transfer of process knowledge, acceptance criteria, receiving-site capability, required qualification or validation, approved documents, and personnel competence. The appropriate evidence depends on the product and process; a generic checklist cannot replace a documented assessment. Finally, verify implementation where the work happens. Confirm that current instructions are available, suppliers received approved requirements, systems contain correct versions, and affected personnel can perform their tasks. A signed approval is not evidence that every downstream change took effect. Mistakes That Undermine Inspection Readiness Closing CAPAs on task completion alone: Effectiveness checks should test whether the underlying failure has been controlled. Updating labels in isolation: Assess packaging, supplier, system, documentation, and inventory consequences. Counting closures instead of evidence: Dashboards need defensible records behind their status indicators. ...

State of API & Peptide CDMO Capacity

Pharmaceutical companies planning peptide or complex small-molecule launches are...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »